Table 3 Biomarker analysis in matched specimens
From: Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
Biomarker | Number | Mean | SD | P-value |
|---|---|---|---|---|
Ki67 | ||||
Pre-lapatinib | 16 | 26.81 | 12.303 | 0.051 |
Post-lapatinib | 16 | 32.44 | 14.166 | |
p27 | ||||
Pre-lapatinib | 15 | 17.67 | 21.672 | 0.127 |
Post-lapatinib | 15 | 8.73 | 15.050 | |
pHER2 | ||||
Pre-lapatinib | 13 | 237.08 | 63.357 | 0.000 |
Post-lapatinib | 13 | 79.85 | 104.311 | |
pERK-1 | ||||
Pre-lapatinib | 16 | 117.44 | 84.806 | 0.005 |
Post-lapatinib | 16 | 45.19 | 84.673 | |
pAKt | ||||
Pre-lapatinib | 15 | 106.33 | 93.512 | 0.620 |
Post-lapatinib | 15 | 117.00 | 88.657 |